# CJC-1295 Dosage in the Research Literature

> CJC-1295 dosage as studied: human pharmacokinetic studies used single subcutaneous doses of 30, 60 or 90 ug/kg. Research-context only; CJC-1295 has no established human dose.

The doses administered to which species, by which route, in published studies — not a protocol, not a recommendation. CJC-1295 has no established human therapeutic dose.

## Doses Used in the Research Literature

CJC-1295 dosage in the published literature is straightforward to summarize. Human pharmacokinetic studies used single subcutaneous doses of 30, 60 or 90 micrograms per kilogram [1][3]. The GHRH-knockout mouse growth study used 2 micrograms per dose at 24-, 48- or 72-hour intervals, with the once-every-24-hours schedule fully normalizing growth [4].

These are the figures that exist in the peer-reviewed record. By contrast, community and clinic 'protocols' for the no-DAC Modified GRF (1-29) and for CJC-1295/ipamorelin commonly cite 100-300 microgram fixed doses, but those are not derived from controlled human trials [1]. There is no established human therapeutic dose of CJC-1295, because it is an unapproved research chemical with no approved indication [1]. Everything below describes research methodology, not a course of use.

## The dose-response seen in studies

Within the studied range, the response was dose-dependent. In healthy adults, single subcutaneous doses of 30 or 60 micrograms per kilogram produced 2- to 10-fold increases in mean plasma GH for six days or more and 1.5- to 3-fold increases in IGF-1 for 9 to 11 days, with the larger dose generally driving the larger and longer response [1]. The companion study in healthy men used 60 or 90 micrograms per kilogram and measured a roughly 7.5-fold rise in basal GH and a 46% rise in mean GH one week out [3].

The animal work anchors the lower end of the picture. In GHRH-knockout mice, 2 micrograms of CJC-1295 given once every 24 hours fully normalized body weight and length, while the same dose spaced to every 48 or 72 hours was progressively less effective — so in that model the interval mattered as much as the amount [4]. These are the figures the peer-reviewed record actually contains; they describe how the kinetics and the growth response were characterized, in defined species, at defined doses [1][3][4].

## Studied doses versus circulating protocols

There is a real gap between what was studied and what circulates online. The human studies dosed by body weight, in micrograms per kilogram, to characterize pharmacokinetics [1][3]. The fixed-dose 'protocols' that circulate for the no-DAC Modified GRF (1-29) and for CJC-1295/ipamorelin — commonly cited around 100-300 micrograms — are not derived from controlled human trials [1]. The two are not interchangeable: a weight-based PK study dose is a measurement tool, not a regimen.

The CJC-1295/ipamorelin pairing is studied for two-receptor synergy — a GHRH analog plus a selective GH secretagogue acting through distinct receptors — but a validated human dose for the combination is not part of the published record [11]. Because CJC-1295 is an unapproved research chemical with no approved indication, no regulator has set a human dose for any form of it, and this site does not supply one [1].

## Route, handling, and bioavailability

Subcutaneous injection was the primary route in published studies; intravenous dosing was used in the early GRF(1-29) pharmacokinetic work [9]. Oral bioavailability is negligible because CJC-1295 is a peptide and is degraded in the gut [1].

In research handling, the lyophilized peptide is reconstituted with bacteriostatic water and refrigerated [1]. The four substitutions confer resistance to dipeptidylpeptidase-IV and related proteases; in the DAC variant, albumin conjugation confers the multi-day duration of action [2][8]. The molecular handling details — formula, molecular weight near 3367.9 Da, CAS 863288-34-0 — are reference identifiers, not dosing guidance.

## How much CJC-1295 should I take?

Human pharmacokinetic studies used single subcutaneous doses of 30, 60 or 90 micrograms per kilogram; there is no established human therapeutic dose, as CJC-1295 is an unapproved research chemical [1][3]. Those study doses describe how the kinetics were characterized, not a regimen. No regulator has set a CJC-1295 dose for any human indication [1].

## How much CJC-1295 / ipamorelin should I take?

No controlled human trial established a CJC-1295/ipamorelin dose; the pairing is studied for two-receptor (GHRH + GHRP) synergy, but circulating fixed-dose protocols are not trial-derived [11]. The mechanistic case for combining them is sound; a validated human dose for the combination is not part of the published record [11].

## How to reconstitute CJC-1295?

In research handling the lyophilized peptide is reconstituted with bacteriostatic water and refrigerated; oral bioavailability is negligible because it is a peptide [1]. This describes laboratory methodology reported in the literature, not a preparation instruction for human use. The reconstituted peptide's stability rests on the protease-resistant substitutions [8].

## Where to inject CJC-1295?

Subcutaneous injection was the primary route in published studies; intravenous was used in early GRF(1-29) pharmacokinetic work [9]. This describes research methodology, not a human-use recommendation. The subcutaneous route is where the multi-day human kinetics were characterized [1].

---

A marketplace-style listing of the published CJC-1295 record — the DAC and no-DAC forms shelved on separate channels, every figure tagged to its study, nothing here dispensed, prescribed, or for sale.